Drug Trial Radar · NCT02433093
A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Apr 2015
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will assess the safety, tolerability, and pharmacokinetics of basimglurant compared to placebo after multiple ascending oral doses for up to 22 days in healthy subjects and in patients with MDD on stable selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) background therapy.
Conditions
- Major Depressive Disorder, Healthy Volunteer
Interventions
BasimglurantDrug
Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
PlaceboDrug
Participants will receive 22 days of once-daily oral matching placebo capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Incidence of adverse events (AEs)Time frame: Up to 10 weeks
- Safety: Suicidality as assessed using the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 10 weeks
- Safety: Sleep habits as assessed using a participant-recorded sleep diaryTime frame: Up to 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Garden Grove, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.